Link Pharma Chem Limited - Laporan Laba Rugi (TTM)

Link Pharma Chem Limited
IN ˙ BSE
₹ 35.40 ↑1.27 (3.72%)
2025-05-02
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Link Pharma Chem Limited menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 268 294 348 431 494 535 536 518 454 408 388 350 331 312 299 309 296 270 254 244
Change (%) 9.48 18.50 23.75 14.65 8.34 0.09 -3.24 -12.36 -10.27 -4.90 -9.70 -5.45 -5.85 -4.04 3.24 -4.05 -8.77 -5.87 -4.06
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 114 136 190 269 324 369 372 349 294 244 222 201 202 190 173 162 152 137 129 139
Change (%) 19.40 39.90 42.03 20.20 13.96 0.88 -6.22 -15.85 -16.74 -9.28 -9.38 0.71 -6.13 -8.97 -6.36 -6.10 -10.07 -5.68 7.88
% of Revenue 42.30 46.13 54.46 62.50 65.52 68.92 69.47 67.33 64.64 59.98 57.21 57.42 61.15 60.97 57.84 52.46 51.34 50.61 50.71 57.02
Gross Operating Profit 155 158 159 162 170 166 164 169 161 163 166 149 129 122 126 147 144 133 125 105
Change (%) 2.21 0.18 1.90 5.42 -2.34 -1.68 3.55 -5.16 1.57 1.66 -10.12 -13.74 -5.42 3.66 16.42 -1.80 -7.40 -6.06 -16.33
% of Revenue 57.70 53.87 45.54 37.50 34.48 31.08 30.53 32.67 35.36 40.02 42.79 42.58 38.85 39.03 42.16 47.54 48.66 49.39 49.29 42.98
SG&A 50 52 56 59 55 54 58 58 63 63 61 56 58 58 55 55 56 55 54 56
Change (%) 4.41 7.81 4.33 -7.31 -1.53 7.64 -0.03 8.91 -0.31 -3.06 -7.19 3.34 0.18 -5.37 -0.72 2.21 -2.17 -1.81 4.12
% of Revenue 18.67 17.81 16.20 13.66 11.04 10.04 10.79 11.15 13.86 15.40 15.70 16.13 17.63 18.76 18.50 17.79 18.95 20.32 21.20 23.01
R&D
Change (%)
% of Revenue
OpEx 238 263 326 406 466 507 510 494 430 387 370 351 345 335 316 310 292 267 262 251
Change (%) 10.26 23.84 24.66 14.92 8.66 0.62 -3.08 -12.92 -10.15 -4.40 -5.18 -1.60 -2.98 -5.62 -1.77 -6.00 -8.43 -1.71 -4.29
% of Revenue 88.84 89.47 93.50 94.19 94.40 94.69 95.19 95.35 94.75 94.87 95.37 100.14 104.21 107.40 105.63 100.50 98.47 98.83 103.20 102.94
Operating Income 30 31 23 25 28 28 26 24 24 21 18 -0 -14 -23 -17 -2 5 3 -8 -7
Change (%) 3.29 -26.88 10.72 10.42 2.83 -9.48 -6.45 -0.92 -12.38 -14.15 -102.79 2,688.20 65.28 -26.91 -90.80 -392.90 -30.22 -356.98 -11.75
% of Revenue 11.16 10.53 6.50 5.81 5.60 5.31 4.81 4.65 5.25 5.13 4.63 -0.14 -4.21 -7.40 -5.63 -0.50 1.53 1.17 -3.20 -2.94
Interest Expense -4 -4 -4 -5 -5 -5 -5 -5 -5 -5 -8 -8 -9 -9 -9 -9 -9 -8 -8 -7
Change (%) 6.79 10.74 5.85 -2.81 8.50 -8.22 3.61 9.11 6.98 39.45 7.96 9.34 4.30 -6.93 -0.96 -1.08 -2.97 -6.44 -15.00
% of Revenue -1.39 -1.35 -1.27 -1.08 -0.92 -0.92 -0.84 -0.90 -1.12 -1.34 -1.96 -2.35 -2.71 -3.01 -2.92 -2.80 -2.88 -3.07 -3.05 -2.70
Net Income 12 12 11 12 14 18 19 11 16 11 7 1 -19 -18 -14 -2 5 -4 -10 -9
Change (%) -1.26 -11.03 15.05 12.03 26.15 6.67 -41.49 49.35 -31.80 -41.66 -81.06 -1,599.76 -2.25 -24.96 -82.13 -293.47 -188.50 146.30 -10.27
% of Revenue 4.60 4.15 3.12 2.90 2.83 3.30 3.51 2.12 3.62 2.75 1.69 0.35 -5.61 -5.83 -4.56 -0.79 1.59 -1.54 -4.04 -3.78

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista